Biogen: 3 Key Takeaways for Long-Term Investors

Source Motley_fool

Key Points

  • Total third quarter core pharmaceutical revenue reached $2 billion.

  • Growth portfolio revenue rose 49% year over year in Q3.

  • Biogen repaid $400 million of term loans during the third quarter.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

On its third-quarter 2026 earnings call, held on Oct. 28, 2026, Biogen (NASDAQ:BIIB) announced that it's on track to deliver full-year top-line growth, driven by core commercial expansion and the performance of acquired products. A stabilizing core portfolio alongside faster growth from newly acquired therapies gives the business a durable revenue foundation. That stability allows the company to execute on its pipeline of late-stage drug candidates without relying entirely on unproven clinical trials.

Three things management said stand out.

1. Acquisition Accelerates Revenue Base Independence

The acquisition of Apellis Pharmaceuticals added SYFOVRE, a therapy for geographic atrophy, an eye condition, and Empaveli, a drug for rare kidney and blood disorders, creating a $1 billion annual run-rate asset base. Cost synergies arrived ahead of schedule, so operating dilution is now negligible.

The first point I would make on that is given the Appellis acquisition, we now think that the company can grow even without the pipeline.
-- Christopher A. Viehbacher, President and Chief Executive Officer

2. High-Dose SPINRAZA Conversion Strengthens Rare Disease Leadership

Conversion to high-dose SPINRAZA, a treatment for spinal muscular atrophy (SMA), a genetic neuromuscular disorder, exceeded internal targets during the quarter. Patients and prescribers are moving quickly to the elevated dose, providing strong momentum for the rare disease franchise.

At the end of Q3, 70% of the 12 mg patients now have a start form submitted, which is very high. And we know that 50% have now been dosed the product.
-- Alisha Alaimo, President North America

3. Registrational Data Readouts Set Up Multiyear Growth Potential

Late-stage clinical trials are approaching key milestones, beginning with phase 3 studies for litifilumab in systemic lupus erythematosus (SLE), an autoimmune disease affecting multiple organs. Upcoming readouts across immunology and kidney disease offer multiple opportunities to expand the commercial footprint.

Beyond that, we expect to continue our multiyear cycle of important registrational data flow through the end of the decade.
-- Priya Singhal, Head of Development

Looking Ahead

Core pharmaceutical revenue expanded 18% year over year, proving that commercial execution and product integration are driving top-line acceleration across key markets.

In closing, Q3 26 was another strong quarter and a continuation of the momentum we have seen this year.
-- Robin C. Kramer, Chief Financial Officer

Durable legacy treatments, expanding commercial reach in rare diseases, and accelerated cost synergies give the business distinct structural advantages. Management is watching upcoming phase 3 trial readouts, reimbursement expansion for subcutaneous treatments, and disciplined term loan debt repayment. These operational levers align to support multiyear growth while maintaining balance sheet flexibility.

And I think you know, if we have reasonable success with the pipeline, you know, again, we have to wait and see the results, but there is a good potential that the company can just grow now for the foreseeable future.
-- Christopher A. Viehbacher, President and Chief Executive Officer

Should you buy stock in Biogen right now?

Before you buy stock in Biogen, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Biogen wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $327,620!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $959,410!*

Now, it’s worth noting Stock Advisor’s total average return is 802% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 17, 2026.

The Motley Fool recommends Biogen. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Gold Price Today: Can XAU/USD Hold $3,870? | Mitrade AUGold rebounds near US$3,870 after hitting a one-year low. Explore XAU/USD support, Fed risks and what the outlook means for Australian traders.
Author  Mitrade Team
13 hours ago
Gold rebounds near US$3,870 after hitting a one-year low. Explore XAU/USD support, Fed risks and what the outlook means for Australian traders.
placeholder
Nvidia faces its biggest earnings test yet — why Silicon Valley billionaires want Jensen Huang backNvidia faces a critical earnings test as investors weigh its AI growth outlook and leadership uncertainty. Discover why Silicon Valley billionaires want Jensen Huang back, what it could mean for Nvidia shares and how the results may shape the broader AI trade.
Author  Mark Garro
19 hours ago
Nvidia faces a critical earnings test as investors weigh its AI growth outlook and leadership uncertainty. Discover why Silicon Valley billionaires want Jensen Huang back, what it could mean for Nvidia shares and how the results may shape the broader AI trade.
placeholder
Berkshire Hathaway's Only New Q3 Position Is a Company Few Investors RecognizeBerkshire Hathaway’s only new third-quarter position is a Bending Spoons stake worth $689 million on Sept. 30. The Italian company, listed on Nasdaq as BSP, owns AOL, Evernote, and Vimeo.Berkshire’s F
Author  Beincrypto
19 hours ago
Berkshire Hathaway’s only new third-quarter position is a Bending Spoons stake worth $689 million on Sept. 30. The Italian company, listed on Nasdaq as BSP, owns AOL, Evernote, and Vimeo.Berkshire’s F
placeholder
Stocks, Gold, and Asia Bleed $2.2 Trillion: Top 5 Factors That Triggered the CrashGlobal markets lost roughly $2.2 trillion on November 16 as US stocks, precious metals, and Asian equities sold off together. Technology and AI-linked names led the decline.However, the rout did not s
Author  Beincrypto
19 hours ago
Global markets lost roughly $2.2 trillion on November 16 as US stocks, precious metals, and Asian equities sold off together. Technology and AI-linked names led the decline.However, the rout did not s
placeholder
Tom Lee Sees No Cracks in the AI Trade Despite Nasdaq's 12% DropTom Lee, head of research at Fundstrat Global Advisors, says the artificial intelligence (AI) trade remains structurally intact. The tech-heavy Nasdaq Composite had fallen nearly 12% from its Oct. 6 r
Author  Beincrypto
19 hours ago
Tom Lee, head of research at Fundstrat Global Advisors, says the artificial intelligence (AI) trade remains structurally intact. The tech-heavy Nasdaq Composite had fallen nearly 12% from its Oct. 6 r
goTop
quote